================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported) October 31, 2006

                             HAEMONETICS CORPORATION
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Massachusetts                   1-10730                  04-2882273
 -----------------------------         ------------          -------------------
 (State or other jurisdiction          (Commission            (I.R.S. Employer
       of incorporation)               File Number)          Identification No.)

                      400 Wood Road                                  02184
          ----------------------------------------                 ----------
          (Address of principal executive offices)                 (Zip Code)

         Registrant's telephone number, including area code 781-848-7100


         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 2.02   RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On October 31, 2006 Haemonetics Corporation (the "Company") issued a press
release announcing financial results for the second quarter and six months ended
September 30, 2006. A copy of the release is furnished with this report as
exhibit 99.1.

The information in this current report on Form 8-K and the exhibit attached
hereto shall not be deemed "filed" for the purposes of Section 18 of the
Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such filing.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1: Press Release of Haemonetics Corporation dated October 31, 2006 announcing
      financial results for the second quarter and six months ended
      September 30, 2006.

                                        2


                                   SIGNATURES

            Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                                        HAEMONETICS CORPORATION
                                                        ------------------------
                                                        (Registrant)


Date:  October 31, 2006                                 /s/ RONALD J. RYAN
                                                        ------------------------
                                                        Ronald J. Ryan,
                                                        Vice President and
                                                        Chief Financial Officer

                                        3